Vir Biotechnology (VIR) FY2022 results: revenue $1.6 billion, up 47.5% on the year
Vir Biotechnology, Inc. (VIR) reported revenue of $1.6 billion for fiscal 2022, the year ended 31 December 2022, up 47.5% on the year before. Net income was $516 million, down 2.4%, and diluted earnings per share $3.83. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2023.
Revenue
$1.6 billion
+47.5% on the year
FY2017FY2022
Operating margin
51.6%
38.4% a year earlier
FY2017FY2022
Net income
$516 million
-2.4% on the year
FY2017FY2022
Diluted EPS
$3.83
-3.3% on the year
FY2017FY2022
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Operating cash flow
1,663
-47.6
-191
Capital expenditure
68.0
21.8
6.5
+211.8%
Free cash flow
1,595
-69.4
-197
Free cash flow margin
98.7%
-6.3%
-258.6%
Cash from investing
-1,193
-141
-9.9
Cash from financing
34.8
100
529
-65.4%
Depreciation and amortisation
6.8
5.3
4.4
+28.5%
Share-based compensation
102
83.8
27.6
+21.8%
Diluted shares, weighted
135m
133m
119m
+1.0%
Shares outstanding at period end
133m
131m
127m
+1.6%
Balance sheet
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Shareholders' equity
2,078
1,432
717
+45.1%
Non-controlling interest
0.0
n/a
n/a
Debt
0.0
0.0
0.0
Operating lease liabilities
124
134
66.6
-7.3%
Finance lease liabilities
n/a
n/a
0.7
Other liabilities
600
389
135
+54.4%
Total liabilities and equity
2,802
1,954
919
+43.4%
Fixed assets
106
42.8
17.9
+146.6%
Goodwill
16.9
16.9
16.9
0.0%
Intangible assets
32.8
33.3
33.8
-1.6%
Investments
1,545
419
300
+269.2%
Cash and equivalents
849
348
437
+144.0%
Receivables
0.0
773
0.0
Other assets
253
322
113
-21.5%
Total assets
2,802
1,954
919
+43.4%
10-K for the year ended 31 December 2022, filed 28 February 2023: the filing.